United Therapeutics Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 04, 2021 at 06:05 am EDT
Share
United Therapeutics Corporation announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 446.5 million compared to USD 362 million a year ago. Operating income was USD 222.2 million compared to USD 140.5 million a year ago. Net income was USD 172.6 million compared to USD 107.1 million a year ago. Basic earnings per share from continuing operations was USD 3.85 compared to USD 2.43 a year ago. Diluted earnings per share from continuing operations was USD 3.65 compared to USD 2.41 a year ago. For the half year, total revenue was USD 825.6 million compared to USD 718.3 million a year ago. Operating income was USD 157.4 million compared to USD 307.2 million a year ago. Net income was USD 200.9 million compared to USD 244.8 million a year ago. Basic earnings per share from continuing operations was USD 4.49 compared to USD 5.56 a year ago. Diluted earnings per share from continuing operations was USD 4.28 compared to USD 5.53 a year ago.
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.
UNITED THERAPEUTICS CORPORATION 
